The Risk Of Cardiovascular Diseases
A study found a higher risk of cardiovascular diseases (CVD) in patients with type 2 diabetes and low levels (less than 2.0 mmol/L) of low-density lipoprotein cholesterol (LDL-C). The author of the study was Shahnam Sharif, MD, and the study published online in the Diabetes Care.
Side Effects Of Glucocorticoid Treatment
A study by Mohammad Movahedi, M.D., Ph.D., to find out the link between the effects of glucocorticoid treatment and the risk of diabetes mellitus in patients with rheumatoid arthritis shows an increased risk of diabetes mellitus (DM) with the glucocorticoid treatment.
The study was done on the basis of the dosage and timing of glucocorticoid use. The study was published in the Arthritis and Rheumatology.
Devices From Medtronic And Qualcomm
Medtronic (MDT) partners with Qualcomm to develop a disposable continuous glucose monitor (CGM). The product will give better care and treatment to patients with type 2 diabetes (T2D).
Medtronic has partnered with a number of companies during the last one year in the field of diabetes. Some of the companies are.
They recently acquired Smith & Nephew's Gynecology Business.
The Risk For Microvascular Disease Manifestations
The study shows that the chances of major cardiovascular disease (CVD) can increase with the number of microvascular disease manifestations in patients with type 2 diabetes (T2D). The following are the microvascular diseases.
The study was published in the Lancet Diabetes & Endocrinology.
The Risk From Poor Lifestyle
The healthcare experts from the United Kingdom called for 100,000 weight loss surgeries to reduce the body mass index (BMI) of patients with type 2 diabetes (T2D).
An earlier study has indicated that weight loss surgery can reverse type 2 diabetes (T2D) with the reduction of BMI. The following are the major health complications associated with type 2 diabetes (T2D).
Even though there is a high risk associated with diabetes, it was reported that less than 50% of patients are making lifestyle changes or drugs to control high blood sugar levels.
The Health Risk Associated With Amyloid Proteins
Proteins are normally soluble in water. If the proteins could not fold properly, they can become insoluble and can be deposited in organs and tissues. The protein deposits can disrupt the function of the body organs.
Amyloids are the misfolded proteins. The accumulation of amyloid in our organs is known as amyloidosis.
The researchers from Uppsala University, Sweden have found that amyloids in the brain can influence the growth of the fine fiber in the pancreas.
The islet amyloid polypeptide (IAPP) is normally associated with patients with type 2 diabetes (T2D). The accumulation of the Islet amyloid polypeptide (IAPP) can lower the brain function and may lead to the death of the brain cells.
Discovery Of TSPAN2 Protein
A study by the Korea Basic Science Institute shows that the TSPAN2, a protein found in the pancreas, can play an important role in the prevention of the death of beta cells induced by the high blood glucose levels.
The researchers say that the new medicines have to be developed to stop the loss (or death) of beta cells by targeting the TSPAN2 protein. The author of the study was Ik-Soon Jang. The study was published in the FASEB Journal.
Approval Of Diabetes Combination Drug from AstraZeneca
The Medicinal Products Committee of European regulator supported the approval of diabetes combination drug from AstraZeneca. Earlier, FDA did not approve the drug and asked for more information.
AstraZeneca says that the US regulator did not approve diabetes combination drug as the drug has high levels of potassium. Diabetes combination drug from AstraZeneca is a combination of saxagliptin and dapagliflozin.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.